DOPAMINE BETA HYDROXYLASE

/ SCIENCE, SOLUTIONS / By
  1. Serum DOPAMINE–BETA–HYDROXYLASE activity
  2. DOPAMINE BETA–HYDROXYLASE deficiency. A genetic disorder of cardiovascular regulation.
  3. DOPAMINE BETA–HYDROXYLASE of adrenal chromaffin granules: structure and function
  4. DOPAMINE BETA–HYDROXYLASE deficiency
  5. Reduced DOPAMINE–BETA–HYDROXYLASE activity in Alzheimer’s disease
  6. DOPAMINE BETA–HYDROXYLASE : biochemistry and molecular biology.
  7. Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine HYDROXYLASE and DOPAMINE‐BETA‐HYDROXYLASE
  8. DOPAMINE–BETA–HYDROXYLASE
  9. DOPAMINE BETA‐HYDROXYLASE and its genetic variants in human health and disease
  10. Association of the DOPAMINE BETA HYDROXYLASE gene with attention deficit hyperactivity disorder: genetic analysis of the Milwaukee longitudinal study
  11. Localization of the human DOPAMINE BETA HYDROXYLASE (DBH) gene to chromosome 9q34
  12. Endogenous restoration of noradrenaline by precursor therapy in DOPAMINE–BETA–HYDROXYLASE deficiency
  13. Clinical presentation and long‐term follow‐up of DOPAMINE BETA HYDROXYLASE deficiency
  14. Congenital DOPAMINE–BETA–HYDROXYLASE deficiency: A novel orthostatic syndrome
  15. The primary structure of human DOPAMINE‐BETA‐HYDROXYLASE : insights into the relationship between the soluble and the membrane‐bound forms of the enzyme.
  16. Kinetic and spectroscopic studies of the interaction of copper with DOPAMINE BETA–HYDROXYLASE .
  17. Tyrosine HYDROXYLASE , but not DOPAMINE BETA–HYDROXYLASE , is increased in rat frontal cortex after traumatic brain injury
  18. A genetic association study of migraine with DOPAMINE receptor 4, DOPAMINE transporter and DOPAMINE–BETA–HYDROXYLASE genes
  19. Inheritance of very low serum DOPAMINE–BETA–HYDROXYLASE activity.
  20. DOPAMINE BETA–HYDROXYLASE gene modulates individuals’ empathic ability
  21. Plasma DOPAMINE BETA–HYDROXYLASE activity in psychotic and non-psychotic post-traumatic stress disorder
  22. Mechanism-based inactivation of DOPAMINE. BETA.-HYDROXYLASE by p-cresol and related alkylphenols
  23. Attention deficit hyperactivity disorder and the gene for DOPAMINE BETA–HYDROXYLASE
  24. Regulation of DOPAMINE BETA–HYDROXYLASE in rat adrenal glands.
  25. Association between a 19 bp deletion polymorphism at the DOPAMINE BETA–HYDROXYLASE (DBH) locus and migraine with aura
  26. Neuron-specific expression of the human DOPAMINE BETA–HYDROXYLASE gene requires both the cAMP-response element and a silencer region.
  27. Effects of reserpine on activities and amounts of tyrosine HYDROXYLASE and DOPAMINE–BETA–HYDROXYLASE in catecholamine neuronal systems in rat brain.
  28. Multisubstrate inhibitors of DOPAMINE. BETA.-HYDROXYLASE . 2. Structure-activity relationships at the phenethylamine binding site
  29. DOPAMINE BETA‐HYDROXYLASE (DBH) activity and ‐1021C/T polymorphism of DBH gene in combat‐related post‐traumatic stress disorder
  30. Linkage of a gene regulating DOPAMINE–BETA–HYDROXYLASE activity and the ABO blood group locus.
  31. Ultrastructural demonstration of noradrenergic synapses in the rat central nervous system by DOPAMINE–BETA–HYDROXYLASE immunocytochemistry.
  32. Effects of acupuncture on serum cortisol level and DOPAMINE BETA–HYDROXYLASE activity in normal Chinese
  33. Characterization of a carbon monoxide complex of reduced DOPAMINE BETA–HYDROXYLASE . Evidence for inequivalence of the Cu (I) centers.
  34. Genotype-independent decrease in plasma DOPAMINE BETA–HYDROXYLASE activity in Alzheimer’s disease
  35. Human DOPAMINE BETA–HYDROXYLASE (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure
  36. The DOPAMINE BETA‐HYDROXYLASE inhibitor nepicastat increases DOPAMINE release and potentiates psychostimulant‐induced DOPAMINE release in the prefrontal cortex
  37. Isolation and reconstitution of the membrane-bound form of DOPAMINE BETA–HYDROXYLASE .
  38. … neuronal perikarya and fibres in the brain of a teleost, Gasterosteus aculeatus L. comparison with tyrosine HYDROXYLASE -and DOPAMINE–BETA–HYDROXYLASE …
  39. Functional and high level expression of human DOPAMINE BETA–HYDROXYLASE in transgenic mice.
  40. In vivo cell type-specific CRISPR knockdown of DOPAMINE BETA HYDROXYLASE reduces locus coeruleus evoked wakefulness
  41. DOPAMINE–BETA–HYDROXYLASE in the cerebrospinal fluid of psychiatric patients.
  42. Soluble and membrane-bound forms of DOPAMINE BETA–HYDROXYLASE are encoded by the same mRNA.
  43. Functional model of DOPAMINE. BETA.-HYDROXYLASE . quantitative ligand hydroxylation at the benzylic position of a copper complex by dioxygen
  44. DOPAMINE BETA HYDROXYLASE genotype identifies individuals less susceptible to bias in computer-assisted decision making
  45. Polymorphisms and low plasma activity of DOPAMINE–BETA–HYDROXYLASE in ADHD children
  46. Low DOPAMINE–BETA–HYDROXYLASE : a biological sequela of abuse and neglect?
  47. Development of DOPAMINE‐BETA HYDROXYLASE —positive fiber innervation of the rat hippocampus
  48. Carbonmonoxy DOPAMINE BETA–HYDROXYLASE . Structural characterization by Fourier transform infrared, fluorescence, and x-ray absorption spectroscopy.
  49. DOPAMINE BETA‐HYDROXYLASE (DBH) gene and schizophrenia phenotypic variability: A genetic association study
  50. Selective depletion of cortical noradrenaline by anti-DOPAMINE BETA–HYDROXYLASE –saporin impairs attentional function and enhances the effects of guanfacine in the rat
  51. The expression of dopa decarboxylase and DOPAMINE BETA HYDROXYLASE and their responding to bacterial challenge during the ontogenesis of scallop Chlamys farreri
  52. DOPAMINE BETA–HYDROXYLASE participate in the immunoendocrine responses of hypothermal stressed white shrimp, Litopenaeus vannamei
  53. Regional brain abnormalities in norepinephrine uptake and DOPAMINE BETA–HYDROXYLASE activity in the genetically epilepsy-prone rat.
  54. Positive association between− 1021TT genotype of DOPAMINE BETA HYDROXYLASE gene and progressive behavior of injection heroin users
  55. Design and kinetic characterization of multisubstrate inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  56. Decreased DOPAMINE BETA–HYDROXYLASE activity in unipolar geriatric delusional depression
  57. DOPAMINE–BETA–HYDROXYLASE (DBH) and homovanillic acid (HVA) in autistic children
  58. Cell-specific expression from the human DOPAMINE BETA–HYDROXYLASE promoter in transgenic mice is controlled via a combination of positive and negative regulatory …
  59. … postural hypotension and sympathetic failure due to an inability to synthesize noradrenaline from DOPAMINE because of a deficiency of DOPAMINE BETA HYDROXYLASE
  60. Analysis of DOPAMINE BETA HYDROXYLASE gene polymorphisms in migraine
  61. Association of DOPAMINE BETA–HYDROXYLASE polymorphisms with alzheimer’s disease, Parkinson’s disease and schizophrenia: evidence based on currently available …
  62. Copper K-extended x-ray absorption fine structure studies of oxidized and reduced DOPAMINE BETA–HYDROXYLASE . Confirmation of a sulfur ligand to copper (I) in …
  63. Electron spin-echo studies of the copper (II) binding sites in DOPAMINE. BETA.-HYDROXYLASE
  64. Minor physical anomalies and plasma DOPAMINE–BETA–HYDROXYLASE activity in hyperactive boys
  65. DOPAMINE. BETA.-HYDROXYLASE : activity and inhibition in the presence of. BETA.-substituted phenethylamines
  66. Serum DOPAMINE—BETA—HYDROXYLASE during development of immobilization—induced hypertension
  67. … mediation of the positive reinforcing properties of ethanol: I. Suppression of ethanol consumption in laboratory rats following DOPAMINE–BETA–HYDROXYLASE inhibition.
  68. Cardiovascular effects of a new potent DOPAMINE BETA–HYDROXYLASE inhibitor in spontaneously hypertensive rats.
  69. DOPAMINE–BETA HYDROXYLASE polymorphism and cocaine addiction
  70. Selective inhibition of DOPAMINE‐BETA‐HYDROXYLASE enhances DOPAMINE release from noradrenergic terminals in the medial prefrontal cortex
  71. Association between DOPAMINE BETA HYDROXYLASE rs5320 polymorphism and smoking behaviour in elderly Japanese
  72. Plasma noradrenaline and DOPAMINE–BETA–HYDROXYLASE during human sexual activity
  73. The copper sites of DOPAMINE. BETA.-HYDROXYLASE : an x-ray absorption spectroscopic study
  74. Release of catecholamines and DOPAMINE BETA‐HYDROXYLASE from the perfused adrenal gland of the cat.
  75. Inactivation of DOPAMINE. BETA.-HYDROXYLASE by p-cresol: isolation and characterization of covalently modified active site peptides
  76. Human plasma DOPAMINE BETA–HYDROXYLASE . Purification and properties.
  77. Involvement of DOPAMINE BETA–HYDROXYLASE in the neuroendocrine-immune regulatory network of white shrimp, Litopenaeus vannamei
  78. The mechanism of inactivation of DOPAMINE BETA–HYDROXYLASE by hydrazines.
  79. Suppression of ethanol intake following administration of DOPAMINE–BETA–HYDROXYLASE inhibitors in rats.
  80. Antihypertensive effect of a DOPAMINE BETA HYDROXYLASE inhibitor, bupicomide: a comparison with hydralazine
  81. Plasma norepinephrine concentration and plasma DOPAMINE–BETA–HYDROXYLASE activity in patients with congestive heart failure.
  82. Multisubstrate inhibitors of DOPAMINE. BETA.-HYDROXYLASE . 1. Some 1-phenyl and 1-phenyl-bridged derivatives of imidazole-2-thione
  83. Plasma adrenaline and noradrenaline concentrations and DOPAMINE–BETA–HYDROXYLASE activity in myocardial infarction with and without cardiogenic shock.
  84. … catecholaminergic modulation of visual attention: differential effects of catechol-O-methyltransferase and DOPAMINE BETA–HYDROXYLASE genes on visual …
  85. Analysis of the DOPAMINE BETA HYDROXYLASE gene in Gilles de la Tourette syndrome
  86. Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in DOPAMINE BETA HYDROXYLASE knockout mice
  87. Reflex control of sympathetic nerve activity in DOPAMINE BETA–HYDROXYLASE deficiency.
  88. DOPAMINE BETA–HYDROXYLASE activity in cerebrospinal fluid of parkinsonian patients
  89. Mechanism of biosynthesis of soluble and membrane-bound forms of DOPAMINE BETA–HYDROXYLASE in PC12 pheochromocytoma cells.
  90. Bovine DOPAMINE BETA–HYDROXYLASE cDNA. Complete coding sequence and expression in mammalian cells with vaccinia virus vector.
  91. Changes of DOPAMINE–BETA–HYDROXYLASE activity during ontogenesis in healthy subjects and in an experimental model (rats)
  92. Human pheochromocytoma DOPAMINE–BETA–HYDROXYLASE : purification and molecular parameters of the tetramer
  93. Asymmetric sulfoxidation by DOPAMINE. BETA.-HYDROXYLASE , an oxygenase heretofore considered specific for methylene hydroxylation
  94. The cAMP-dependent protein kinase regulates transcription of the DOPAMINE BETA–HYDROXYLASE gene
  95. … noradrenergic axons to systemically administered DSP-4 in the rat: an immunohistochemical study using antibodies to noradrenaline and DOPAMINE–BETA–HYDROXYLASE …
  96. … : linkage analysis excludes a role for the genes coding for DOPAMINE D1, D2, D3, D4, D5 receptors, DOPAMINE BETA HYDROXYLASE , tyrosinase, and tyrosine HYDROXYLASE
  97. Preparation and Characterization of Half-Apo DOPAMINE-. BETA.-HYDROXYLASE by Selective Removal of CuA. Identification of a Sulfur Ligand at the Dioxygen Binding …
  98. Serum DOPAMINE–BETA–HYDROXYLASE activity: Clinical applications in child psychiatry
  99. Human serum DOPAMINE BETA–HYDROXYLASE : correlation of enzymatic activity with immunoreactive protein in genetically defined samples.
  100. Deduction of kinetic mechanism in multisubstrate enzyme reactions from tritium isotope effects. Application to DOPAMINE BETA–HYDROXYLASE .
  101. Subunit exchange between membranous and soluble forms of bovine DOPAMINE BETA–HYDROXYLASE .
  102. Impaired temporal resolution of visual attention and DOPAMINE BETA HYDROXYLASE genotype in attention-deficit/hyperactivity disorder
  103. Association between DOPAMINE BETA HYDROXYLASE gene and attention deficit hyperactivity disorder complicated with disruptive behavior disorder
  104. Mechanism-based inhibitors of DOPAMINE. BETA.-HYDROXYLASE containing acetylenic or cyclopropyl groups
  105. Measurement of human DOPAMINE–BETA–HYDROXYLASE in serum by homologous radioimmunoassay.
  106. Alternate substrates of DOPAMINE BETA–HYDROXYLASE . I. Kinetic investigations of benzyl cyanides as substrates and inhibitors.
  107. Serum DOPAMINE–BETA–HYDROXYLASE in affective disorders
  108. DOPAMINE BETA HYDROXYLASE (DBH) plasma activity in childhood mental disorders
  109. Antihypertensive activities of phenyl aminoethyl sulfides, a class of synthetic substrates for DOPAMINE. BETA.-HYDROXYLASE
  110. Increased ganglionic tyrosine HYDROXYLASE and DOPAMINE–BETA–HYDROXYLASE activities following preganglionic nerve stimulation: role of nicotine receptors.
  111. The pH-dependent subunit dissociation and catalytic activity of bovine DOPAMINE BETA–HYDROXYLASE .
  112. The role of norepinephrine in the function of the area postrema. I. Immunofluorescent localization of DOPAMINE–BETA–HYDROXYLASE and electron microscopy
  113. Partial characterization of a naturally occurring inhibitor of DOPAMINE BETA–HYDROXYLASE .
  114. Decreased serum DOPAMINE–BETA–HYDROXYLASE in hyperthyroidism
  115. The activity of DOPAMINE–BETA–HYDROXYLASE and methionine-activating enzyme in blood of schizophrenic patients.
  116. … -substituted imidazoles, triazoles, tetrazoles, pyridinethiones, and structural relatives as multisubstrate inhibitors of DOPAMINE. BETA.-HYDROXYLASE . 4. Structure-activity …
  117. Linkage disequilibrium analysis of the DOPAMINE BETA–HYDROXYLASE gene in persistent attention deficit hyperactivity disorder
  118. Unsaturated heterocyclic amines as potent time-dependent inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  119. Analysis of polymorphisms in the DOPAMINE BETA HYDROXYLASE gene: association with attention deficit hyperactivity disorder in Indian children
  120. Platelet monoamine oxidase, plasma DOPAMINE–BETA–HYDROXYLASE and attention in a” biochemical high risk” sample.
  121. Sleep patterns in congenital DOPAMINE BETA–HYDROXYLASE deficiency
  122. Effects of disulfiram and DOPAMINE BETA–HYDROXYLASE knockout on cocaine-induced seizures
  123. Complete Assignment of Disulfide Bonds in Bovine DOPAMINE. BETA.-HYDROXYLASE
  124. 3-Phenylpropenes as mechanism-based inhibitors of DOPAMINE. BETA.-HYDROXYLASE : evidence for a radical mechanism
  125. ABO B gene is associated with introversion personality tendancies through linkage with DOPAMINE BETA HYDROXYLASE gene
  126. DOPAMINE–BETA–HYDROXYLASE in behaviorally disturbed youth: Relationship between teacher and parent ratings
  127. Release of norepinephrine and DOPAMINE–BETA–HYDROXYLASE by nerve stimulation. IV. An evaluation of a role for cyclic adenosine monophosphate.
  128. Purified cytochrome b561 catalyzes transmembrane electron transfer for DOPAMINE BETA–HYDROXYLASE and peptidyl glycine alpha-amidating monooxygenase …
  129. Lack of significant association between− 1021C→ T polymorphism in the DOPAMINE BETA HYDROXYLASE gene and attention deficit hyperactivity disorder
  130. Plasma DOPAMINE BETA–HYDROXYLASE : rapid diagnostic test for recurrent hereditary polyserositis
  131. The distribution of DOPAMINE–BETA–HYDROXYLASE , neuropeptide Y and galanin in locus coeruleus neurons.
  132. Identification and functional characterisation of a novel DOPAMINE BETA HYDROXYLASE gene variant associated with attention deficit hyperactivity disorder
  133. A DOPAMINE BETA HYDROXYLASE from Chlamys farreri and its induced mRNA expression in the haemocytes after LPS stimulation
  134. Changes in plasma catecholamines and DOPAMINE BETA–HYDROXYLASE after corrective surgery for coarctation of the aorta.
  135. . BETA.-Substituted phenethylamines as high-affinity mechanism-based inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  136. Can DOPAMINE BETA‐HYDROXYLASE Levels Predict Adverse Reactions to Disulfiram?
  137. DOPAMINE–BETA–HYDROXYLASE activity and catecholamine levels in the plasma of patients with renal failure
  138. Plasma norepinephrine, epinephrine, and DOPAMINE BETA–HYDROXYLASE activity during exercise in man.
  139. Primary amino acid sequence of bovine DOPAMINE BETA–HYDROXYLASE .
  140. Association between DOPAMINE BETA–HYDROXYLASE 19-bp insertion/deletion polymorphism and major depressive disorder
  141. A bifunctional genetic regulatory element of the rat DOPAMINE BETA–HYDROXYLASE gene influences cell type specificity and second messenger-mediated …
  142. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in DOPAMINE–BETA–HYDROXYLASE deficiency
  143. … to the anxiety-modulating effects of offspring contact is associated with innate anxiety and brainstem levels of DOPAMINE BETA–HYDROXYLASE in female laboratory rats
  144. Determination of serum DOPAMINE-. BETA.-HYDROXYLASE activity by reverse-phase liquid chromatography with column switching
  145. The meaning of DOPAMINE BETA–HYDROXYLASE in essential hypertension.
  146. Elevated plasma DOPAMINE BETA HYDROXYLASE activity in rats with neurogenic hypertension
  147. Exocytotic release of catecholamines and DOPAMINE–BETA–HYDROXYLASE from the perfused adrenal gland of the rabbit and cat.
  148. DOPAMINE BETA–HYDROXYLASE inhibition in a patient with Wilson’s disease and manic symptoms.
  149. The effect of some dithiocarbamic acids on DOPAMINE–BETA–HYDROXYLASE and catecholamines level in rat’s brain.
  150. Effect of acute volume alterations on norepinephrine and DOPAMINE–BETA–HYDROXYLASE in normotensive and hypertensive subjects.
  151. DOPAMINE–BETA–HYDROXYLASE : an index of adrenergic function in hypertensive patients
  152. Association of DOPAMINE BETA–HYDROXYLASE polymorphism with attention deficit hyperactivity disorder in children
  153. Maternal and fetal plasma renin and DOPAMINE–BETA–HYDROXYLASE activities in toxemic pregnancy.
  154. Nerve stimulation-meditated overflow of norepinephrine and DOPAMINE–BETA–HYDROXYLASE . III. Effects of norepinephrine depletion on the alpha presynaptic regulation …
  155. Association of a DOPAMINE BETA–HYDROXYLASE gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction
  156. Inhibition of DOPAMINE. BETA.-HYDROXYLASE by 5-phenoxymethyl-2-oxazolidinethiones
  157. Localization of DOPAMINE–BETA–HYDROXYLASE -like immunoreactivity in the superior olivary complex of the rat.
  158. DOPAMINE–BETA–HYDROXYLASE 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine
  159. An acetylenic mechanism-based inhibitor of DOPAMINE BETA–HYDROXYLASE .
  160. Plasma noradrenaline and DOPAMINE–BETA–HYDROXYLASE during sexual activity
  161. Mosaic deletion 11p13 in a child with DOPAMINE BETA‐HYDROXYLASE deficiency—Case report and review of the literature
  162. … reinforcing properties of ethanol: II. Extinction of ethanol-drinking behavior in laboratory rats by inhibition of DOPAMINE–BETA–HYDROXYLASE . Implications for treatment …
  163. Active site of DOPAMINE. BETA.-HYDROXYLASE . Comparison of enzyme derivatives containing four and eight copper atoms per tetramer using potentiometry and EPR …
  164. Noradrenergic innervation of the human adrenal cortex as revealed by DOPAMINE–BETA–HYDROXYLASE immunohistochemistry.
  165. A Preliminary Study of DBH (Encoding DOPAMINE BETA–HYDROXYLASE ) Genetic Variation and Neural Correlates of Emotional and Motivational …
  166. DOPAMINE BETA–HYDROXYLASE . Inactivation by a suicide substrate.
  167. … in relation to variation in three genes involved in DOPAMINE metabolism: Catechol-O-methyltransferase (COMT), DOPAMINE BETA–HYDROXYLASE (DBH) and monoamine …
  168. Plasma DOPAMINE–BETA–HYDROXYLASE activity in oral contraceptive hypertension.
  169. Serum DOPAMINE–BETA–HYDROXYLASE activity in acute stroke.
  170. Lack of correlation of plasma norepinephrine and DOPAMINE–BETA–HYDROXYLASE in hypertensive and normotensive subjects.
  171. Inhibitors of DOPAMINE. BETA.-HYDROXYLASE . 3. Some 1-(pyridylmethyl) imidazole-2-thiones
  172. Anti-DOPAMINE BETA–HYDROXYLASE immunotoxin-induced sympathectomy in adult rats.
  173. CONCOMITANT ELEVATION OF TYROSINE HYDROXYLASE AND DOPAMINE BETA‐HYDROXYLASE BY CYCLIC AMP IN CULTURED MOUSE …
  174. Segregation and linkage studies of plasma DOPAMINE–BETA–HYDROXYLASE (DBH), erythrocyte catechol-O-methyltransferase (COMT), and platelet monoamine oxidase …
  175. Sulfation and constitutive secretion of DOPAMINE BETA–HYDROXYLASE from rat pheochromocytoma (PC12) cells.
  176. Serum DOPAMINE BETA–HYDROXYLASE activity in menstrual migraine.
  177. Suppression of voluntary ingestion of morphine by inhibition of DOPAMINE–BETA–HYDROXYLASE .
  178. Genes for catecholamine biosynthesis: cloning by expression and identification of the cDNA for rat DOPAMINE BETA–HYDROXYLASE .
  179. The sympathetic skin response in peripheral autonomic failure—evaluation in pure autonomic failure, pure cholinergic dysautonomia and DOPAMINE–BETA–HYDROXYLASE …
  180. ABO group B is associated with personality traits through linkage disequilibrium with low activity DOPAMINE BETA HYDROXYLASE
  181. DOPAMINE BETA–HYDROXYLASE and its role in regulating the growth and larval metamorphosis in Sinonovacula constricta
  182. The DOPAMINE BETA–HYDROXYLASE gene polymorphism rs1611114 is associated with schizophrenia in the Chinese Zhuang but not Chinese Han population
  183. Pharmacological action of FD-008, a new DOPAMINE BETA–HYDROXYLASE inhibitor. I. Effects on blood pressure in rats and dogs.
  184. Effect of Hypophysectomy on Serum DOPAMINE—BETA—HYDROXYLASE Activity in Rat
  185. Kinetic characterization of rat serum DOPAMINE–BETA–HYDROXYLASE using a simplified radioenzymatic assay
  186. Family studies of plasma DOPAMINE–BETA–HYDROXYLASE thermal stability.
  187. Isomer specific kinetics of DOPAMINE BETA–HYDROXYLASE and arylsulfatase towards catecholamine sulfates.
  188. In vivo biosynthesis of two subunit forms of DOPAMINE BETA–HYDROXYLASE in rat brain
  189. Expression of DOPAMINE BETA–HYDROXYLASE in Drosophila Schneider 2 cells. Evidence for a mechanism of membrane binding other than uncleaved signal peptide
  190. PLASMA DOPAMINE‐BETA‐HYDROXYLASE ACTIVITY IN PHAEOCHROMOCYTOMA
  191. Genetic analysis of serum DOPAMINE–BETA–HYDROXYLASE activity in rats
  192. Tissue and plasma catecholamines and DOPAMINE BETA‐HYDROXYLASE activity of various animal species after neurogenic sympathetic stimulation.
  193. Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  194. Bovine DOPAMINE. BETA.-HYDROXYLASE , primary structure determined by cDNA cloning and amino acid sequencing
  195. Isotope effects in the hydroxylation of phenylethylamine by DOPAMINE. BETA.-HYDROXYLASE
  196. Effect of an inhibitor of DOPAMINE–BETA–HYDROXYLASE on the acquisition and retention of four different avoidance tasks in mice
  197. Distribution of DOPAMINE–BETA–HYDROXYLASE -like immunoreactive fibers in the rat cerebellar cortex during ontogeny
  198. On-line synthesis utilizing immobilized enzyme reactors based upon immobilized DOPAMINE BETA–HYDROXYLASE
  199. Serum DOPAMINE–BETA–HYDROXYLASE activity and blood pressure.
  200. Plasma DOPAMINE–BETA–HYDROXYLASE in depressed patients and controls
  201. Clonidine reverses the amnesia induced by DOPAMINE BETA HYDROXYLASE inhibition
  202. Possible increase of DOPAMINE–BETA–HYDROXYLASE activity in the locus ceruleus of paranoid schizophrenic patients: a preliminary post-mortem study
  203. Effect of BETA-adrenergic blockade on circulating catecholamines and DOPAMINE–BETA–HYDROXYLASE activity during exercise in normal subjects
  204. 24-hour DOPAMINE–BETA–HYDROXYLASE pattern: A possible biological index of manic-depression
  205. DOPAMINE BETA HYDROXYLASE gene polymorphism and Parkinson’s disease
  206. Regulation of the multiple forms of DOPAMINE BETA–HYDROXYLASE by nerve growth factor, dexamethasone, and dibutyryl cyclic AMP in the PC12 pheochromocytoma cell …
  207. DOPAMINE–BETA–HYDROXYLASE -positive nerves in normal and transplanted pancreatic tissue in the anterior eye-chamber of rats
  208. Neuropeptide Y plasma levels and serum DOPAMINE–BETA–HYDROXYLASE activity in MS patients with and without abnormal cardiovascular reflexes.
  209. A genetic study of plasma DOPAMINE BETA HYDROXYLASE activity in man
  210. The effects of ganglionic blockade, reserpine and vinblastine on plasma catecholamines and DOPAMINE–BETA–HYDROXYLASE in the rat.
  211. Plasma DOPAMINE–BETA–HYDROXYLASE in identical twins discordant for schizophrenia
  212. … characterization of bipolar affective disorders: a focus on tardive dyskinesia and soft neurological signs in relation to serum DOPAMINE BETA HYDROXYLASE activity
  213. Activity of the enzymes DOPAMINE–BETA–HYDROXYLASE and phenylethanolamine-N-methyltransferase in discrete brain regions of the copper-zinc deficient rat following …
  214. Menstrual cycle and ovarian hormone effects on plasma and platelet monoamine oxidase (MAO) and plasma DOPAMINE–BETA–HYDROXYLASE (DBH) activities in the …
  215. Plasma DOPAMINE–BETA–HYDROXYLASE (DBH) activity during the menstrual cycle
  216. DOPAMINE–BETA–HYDROXYLASE and its apparent endogenous inhibitory activity in the plasma of some psychiatric patients
  217. Glycosylation and membrane insertion of newly synthesized rat DOPAMINE BETA–HYDROXYLASE in a cell-free system without signal cleavage.
  218. Catecholamine metabolites affected by the copper-dependent enzyme DOPAMINE–BETA–HYDROXYLASE provide sensitive biomarkers for early diagnosis of menkes …
  219. Effect of DOPAMINE–BETA–HYDROXYLASE inhibition on cerebral vasospasm in the cat
  220. Serum DOPAMINE BETA–HYDROXYLASE activity following subarachnoid hemorrhage in man.
  221. Highly effective mechanism-based inactivation of DOPAMINE. BETA.-HYDROXYLASE by a novel ketene thioacetal
  222. Active site labeling of DOPAMINE BETA–HYDROXYLASE by two mechanism-based inhibitors: 6-hydroxybenzofuran and phenylhydrazine.
  223. Plasma renin and serum DOPAMINE–BETA–HYDROXYLASE during orthostatic hypotension in quadriplegic man.
  224. Purification and properties of human serum DOPAMINE–BETA–HYDROXYLASE .
  225. Levels of DOPAMINE BETA HYDROXYLASE immunoreactivity in the preoptic hypothalamus of the ovariectomised ewe following injection of oestrogen: evidence for …
  226. Association of DOPAMINE BETA–HYDROXYLASE (DBH) polymorphisms with susceptibility to Parkinson’s disease
  227. Nerve fibers immunoreactive to calcitonin gene-related peptide, substance P, neuropeptide Y, and DOPAMINE BETA–HYDROXYLASE in innervated and denervated oral …
  228. The relationship between serotonin, DOPAMINE BETA HYDROXYLASE and GABA immunoreactive inputs and spinal preganglionic neurones projecting to the major pelvic …
  229. Heart rate variation and serum DOPAMINE–BETA–HYDROXYLASE activity in workers exposed to vibration
  230. Proportions of renal and splenic postganglionic sympathetic populations containing galanin and DOPAMINE BETA HYDROXYLASE
  231. Synthesis of chromogranins and DOPAMINE BETA–HYDROXYLASE by perfused bovine adrenal glands.
  232. Hypertensive crises in quadriplegic patients. Changes in cardiac output, blood volume, serum DOPAMINE–BETA–HYDROXYLASE activity, and arterial prostaglandin PGE2.
  233. Brain DOPAMINE BETA HYDROXYLASE activity: response to stress, tyrosine HYDROXYLASE inhibition, hypophysectomy and ACTH administration
  234. The in situ kinetics of DOPAMINE BETA–HYDROXYLASE in bovine adrenomedullary chromaffin cells. Intravesicular compartmentation reduces apparent affinity for the …
  235. Human plasma DOPAMINE–BETA–HYDROXYLASE : variation in thermal stability
  236. The molecular shape of DOPAMINE BETA–HYDROXYLASE from chromaffin granules of bovine adrenal medulla.
  237. Purification and characterization of avian DOPAMINE. BETA.-HYDROXYLASE
  238. The association of C789A polymorphism in the DOPAMINE BETA–HYDROXYLASE gene (DBH) and aggressive behaviour in dogs
  239. Serum DOPAMINE–BETA–HYDROXYLASE in depressed patients and the effect of electroconvulsive shock treatment
  240. A genetic study of plasma DOPAMINE BETA–HYDROXYLASE in affective disorder.
  241. DOPAMINE BETA HYDROXYLASE : an enzyme with therapeutic potential to combat neural and cardiovascular diseases
  242. Sensation seeking, exercise, and DOPAMINE BETA HYDROXYLASE
  243. Changes in platelet monoamine oxidase and plasma DOPAMINE–BETA–HYDROXYLASE activities in lithium-treated bipolar patients
  244. Inactivation of DOPAMINE. BETA.-HYDROXYLASE by. BETA.-ethynyltyramine: kinetic characterization and covalent modification of an active site peptide
  245. Mechanism-based inhibitors of DOPAMINE. BETA.-HYDROXYLASE : inhibition by 2-bromo-3-(p-hydroxyphenyl)-1-propene
  246. Release of norepinephrine and DOPAMINE–BETA–HYDROXYLASE by nerve stimulation. V. Enhanced release associated with a granular effect of a benzoquinolizine …
  247. Alternate substrates of DOPAMINE BETA–HYDROXYLASE . III. Stoichiometry of the inactivation reaction with benzyl cyanides and spectroscopic investigations.
  248. Association Between DOPAMINE BETA–HYDROXYLASE Gene Polymorphisms and Attention-Deficit Hyperactivity Disorder in Korean Children
  249. Effect of variations in adrenocortical function on DOPAMINE BETA–HYDROXYLASE and norepinephrine in the brain of the rat.
  250. Role of copper and catalytic mechanism in the copper monooxygenase, DOPAMINE BETA–HYDROXYLASE (D BETA H).
  251. Distribution of DOPAMINE BETA–HYDROXYLASE and neuropeptide Y-immunoreactive nerves in healthy equine lungs.
  252. Distribution of DOPAMINE–BETA–HYDROXYLASE —like immunoreactivity in the rat pineal organ
  253. A single nucleotide polymorphism in DOPAMINE BETA HYDROXYLASE (rs6271 (C> T)) is over-represented in inflammatory bowel disease patients and reduces …
  254. Variants of DOPAMINE BETA HYDROXYLASE gene moderate atomoxetine response in children with attention-deficit/hyperactivity disorder
  255. Association of functional DOPAMINE–BETA–HYDROXYLASE (DBH) 19 bp insertion/deletion polymorphism with smoking severity in male schizophrenic smokers
  256. Bovine membranous DOPAMINE BETA–HYDROXYLASE is not anchored via covalently attached phosphatidylinositol.
  257. DOPAMINE BETA–HYDROXYLASE activity in the cat carotid body
  258. Anti-hypertensive effect of acebutolol: its relation to sympathetic nervous system responsiveness and to plasma renin and DOPAMINE–BETA–HYDROXYLASE activities.
  259. Pharmacological action of FD-008, a new DOPAMINE–BETA–HYDROXYLASE inhibitor.
  260. Adenosine 5′-diphosphate-dependent subunit dissociation of bovine DOPAMINE BETA–HYDROXYLASE .
  261. Association between DOPAMINE BETA HYDROXYLASE gene polymorphism and age at onset in male schizophrenia
  262. The influence of DOPAMINE–BETA–HYDROXYLASE and catechol O-methyltransferase gene polymorphism on the efficacy of insulin detemir therapy in patients with …
  263. Generation of two noradrenergic-specific DOPAMINE–BETA–HYDROXYLASE -FLPo knock-in mice using CRISPR/Cas9-Mediated targeting in embryonic stem cells
  264. Some characteristics of amnesia induced by FLA-63 an inhibitor of DOPAMINE BETA HYDROXYLASE
  265. Effects of various inhibitors of tyrosine HYDROXYLASE and DOPAMINE BETA–HYDROXYLASE on rat self-stimulation after reserpine treatment
  266. Effects of aging on the activity of hypothalamic DOPAMINE–BETA–HYDROXYLASE during various stages of the estrous cycle in C57BL/6 mice
  267. Relationship to survival of catecholamine levels and DOPAMINE–BETA–HYDROXYLASE activity in experimental haemorrhagic shock.
  268. Circulating catecholamines, plasma renin and DOPAMINE–BETA–HYDROXYLASE activity with postural stress
  269. Serum DOPAMINE–BETA–HYDROXYLASE activity in women occupationally exposed to carbon disulphide
  270. Serum DOPAMINE–BETA–HYDROXYLASE in diagnostic subgroups of depressed patients and in relation to their personality characteristics
  271. Serum DOPAMINE BETA–HYDROXYLASE activity in essential hypertension.
  272. Alternate substrates of DOPAMINE BETA–HYDROXYLASE . II. Inhibition by benzyl cyanides and reactivation of inhibited enzyme.
  273. Influence of age, sex and hypoxia on plasma DOPAMINE–BETA–HYDROXYLASE activity in the rat.
  274. Concentration of DOPAMINE in plasma, activity of DOPAMINE BETA–HYDROXYLASE in serum and urinary excretion of free catecholamines and vanillylmandelic acid in …
  275. Immunocytochemical colocalizations of insulin, aromatic L-amino acid decarboxylase, DOPAMINE BETA–HYDROXYLASE , S-100 protein and chromogranin A in B-cells of the …
  276. The study of levels of norepinephrine and DOPAMINE–BETA–HYDROXYLASE in patients with pregnancy-induced hypertension.
  277. Effect of unnatural noradrenaline precursor on sympathetic control and orthostatic hypotension in DOPAMINE–BETA–HYDROXYLASE deficiency.
  278. DOPAMINE–BETA–HYDROXYLASE after treatment with BETA-blockers in hypertension.
  279. Effect of monensin on synthesis, post-translational processing, and secretion of DOPAMINE BETA–HYDROXYLASE from PC12 pheochromocytoma cells.
  280. Plasma catecholamines and DOPAMINE–BETA–HYDROXYLASE activity in chronic renal failure
  281. Serum DOPAMINE BETA HYDROXYLASE activity and tardive dyskinesia
  282. … mesenteric ganglion. A. Changes in expression of transmitter-synthesizing enzymes–tyrosine HYDROXYLASE , DOPAMINE BETA–HYDROXYLASE and choline acetyltransferase …
  283. Linkage analysis between manic depressive illness and the DOPAMINE BETA–HYDROXYLASE gene.
  284. Deglycosylated membranous and soluble DOPAMINE BETA–HYDROXYLASE have identical apparent molecular weights
  285. Linkage studies of catechol-O-methyltransferase (COMT) and DOPAMINE–BETA–HYDROXYLASE (DBH) cDNA expression levels
  286. Adrenal origin of the increase in plasma DOPAMINE BETA–HYDROXYLASE and catecholamines induced by hemorrhagic hypotension in dogs.
  287. Normal values for serum DOPAMINE–BETA–HYDROXYLASE activity.
  288. Immunohistochemical colocalization of insulin, aromatic L-amino acid decarboxylase and DOPAMINE BETA–HYDROXYLASE in islet B cells of chicken pancreas
  289. Serum DOPAMINE–BETA–HYDROXYLASE (DBH) activity and blood pressure response of rat strains to shock-induced fighting
  290. Screening of Inhibitory Activity of Edible Mushrooms on DOPAMINE
  291. Adrenal and hypothalamic DOPAMINE‐BETA‐HYDROXYLASE activity in the hamster: Evidence for species‐distinctive day‐night and post‐pinealectomy differences in …
  292. Effect of linoleic acid-rich diet on blood pressure, lipids, catecholamines, and DOPAMINE–BETA–HYDROXYLASE in spontaneously hypertensive rats.
  293. DOPAMINE BETA–HYDROXYLASE inhibition reveals a selective influence of endotoxin on catecholamine content of rat tissues.
  294. Cerebrospinal fluid and plasma DOPAMINE–BETA–HYDROXYLASE activity in human hypertension.
  295. Membrane DOPAMINE BETA–HYDROXYLASE : a precursor for the soluble enzyme in the bovine adrenal medulla.
  296. DOPAMINE BETA–HYDROXYLASE and plasma renin activity in patients with low-, normal-, and high-renin essential hypertension.
  297. Neurochemical studies on tardive dyskinesia. II. Urinary methoxyhydroxyphenylglycol and plasma DOPAMINE–BETA–HYDROXYLASE .
  298. DOPAMINE–BETA–HYDROXYLASE : a modulator of BETA adrenergic receptor activity.
  299. Urinary catecholamine excretion and plasma DOPAMINE–BETA–HYDROXYLASE activity during mental work performed in some periods of menstrual cycle in women.
  300. Sequence tagged site (STS) TaqI RFLP at DOPAMINE BETA–HYDROXYLASE (DBH).
  301. Serum DOPAMINE–BETA–HYDROXYLASE activity in depression and anxiety.
  302. Effect of atropine and acetylcholine on nerve stimulated output of noradrenaline and DOPAMINE–BETA–HYDROXYLASE from isolated rabbit and guinea pig hearts
  303. Changes in tyrosine HYDROXYLASE and DOPAMINE–BETA–HYDROXYLASE activities but not in phenylethanolamine-N-methyltransferase activity within central adrenaline …
  304. Effects of insulin-like growth factor-1 (IGF-1) receptor signaling on rates of apoptosis in retina of DOPAMINE BETA HYDROXYLASE (Dbh−/−) knockout mice
  305. … performance in elderly women: significance of the 19bp insertion/deletion polymorphism in the 5′ flank of the DOPAMINE BETA‐HYDROXYLASE gene, educational level …
  306. Effect of DOPAMINE–BETA–HYDROXYLASE inhibitors on blood pressure and cardiac norepinephrine levels in rats subjected to immobilization stress.
  307. DOPAMINE BETA–HYDROXYLASE in human synovial fluid
  308. Effects of transgenic expression of DOPAMINE BETA HYDROXYLASE (Dbh) gene on blood pressure in spontaneously hypertensive rats
  309. Serum DOPAMINE BETA HYDROXYLASE activity and metoclopramide provocative test in torsion dystonia
  310. Kinetic studies with competitive inhibitors indicate a sequential mechanism for DOPAMINE BETA–HYDROXYLASE .
  311. Plasma DOPAMINE–BETA–HYDROXYLASE activity and catecholamine levels in anesthetized dogs following acute hemorrhage
  312. Effects of the novel DOPAMINE BETA–HYDROXYLASE inhibitor SK&F 102698 on catecholamines and blood pressure in spontaneously hypertensive rats.
  313. … and DOPAMINE–BETA–HYDROXYLASE induced by forced immobilization and insulin-induced hypoglycemia: origin and fate of plasma DOPAMINE–BETA–HYDROXYLASE .
  314. Contribution of adrenal medulla, spleen and lymph, to the plasma levels of DOPAMINE BETA–HYDROXYLASE and catecholamines induced by hemorrhagic …
  315. Plasma and lymph DOPAMINE–BETA–HYDROXYLASE and norepinephrine during carotid occlusion
  316. … of substituted DL-3 (5-benzazolyl) alanines as dopa and alpha-methyldopa analogs and their effects on DOPAMINE BETA–HYDROXYLASE , tyrosinase and diphenoloxidase.
  317. Immunofluorescent patterns of clathrin and DOPAMINE BETA–HYDROXYLASE in chromaffin cells in culture
  318. Plasma DOPAMINE–BETA–HYDROXYLASE activity in depressed patients: role of treatment.
  319. Evidence for inhibition of DOPAMINE–BETA–HYDROXYLASE in vivo after sub-acute pyrazole treatment in rats.
  320. The effects of therapy for mild hypertension on circulating level of DOPAMINE BETA–HYDROXYLASE
  321. Circulating DOPAMINE–BETA–HYDROXYLASE (DBETAH) and catecholamines in a paediatric phaeochromocytoma.
  322. DOPAMINE BETA–HYDROXYLASE gene excluded in four subtypes of hereditary dystonia
  323. Co-expression of tyrosine HYDROXYLASE , DOPAMINE BETA–HYDROXYLASE and neuropeptide Y in the sympathetic neurons projecting to the submandibular gland in the …
  324. Long-term effects of propranolol on tyrosine HYDROXYLASE and DOPAMINE–BETA–HYDROXYLASE in the superior cervical ganglia of the rabbit [proceedings].
  325. Platelet monoamine oxidase and plasma DOPAMINE‐BETA‐HYDROXYLASE activities in patients with multiple sclerosis
  326. Electroacupuncture analgesia is improved by adenoviral gene transfer of DOPAMINE BETA–HYDROXYLASE into the hypothalamus of rats
  327. Anion-and pH-dependent activation of the soluble form of DOPAMINE BETA–HYDROXYLASE
  328. DOPAMINE BETA–HYDROXYLASE inhibition: A potential therapy for the treatment of congestive heart failure
  329. Circulating pool and adrenal soluble content of DOPAMINE BETA–HYDROXYLASE (DBH), in rats, guinea pigs, dogs and humans: their role in determining acute stress …
  330. Immunocytochemical demonstration of DOPAMINE–BETA–HYDROXYLASE and cytochrome B561 on the axonal reticulum in bovine sympathetic neurons.
  331. Synthesis of chromogranin A, DOPAMINE BETA–HYDROXYLASE , and chromaffin vesicles
  332. Evidence that DOPAMINE‐BETA‐HYDROXYLASE immunoreactive neurons in the lateral reticular nucleus project to the spinal cord in the rat
  333. d, l-threo-3, 4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in DOPAMINE BETA–HYDROXYLASE deficiency
  334. Interactions of amphetamine, pimozide, and lithium on plasma norepinephrine and DOPAMINE–BETA–HYDROXYLASE in schizophrenic patients
  335. Prenatal reserpine administration: permanent changes in adrenal tyrosine HYDROXYLASE and DOPAMINE BETA–HYDROXYLASE .
  336. Subunit characterization and primary structure of bovine adrenal medullary DOPAMINE BETA–HYDROXYLASE .
  337. Mechanism of inhibition of DOPAMINE BETA–HYDROXYLASE evoked by FLA-63. An in vitro study.
  338. Plasma DOPAMINE–BETA–HYDROXYLASE and erythrocyte acetylcholinesterase in a group of patients with Parkinson disease
  339. Effect of electroconvulsive treatment on serum DOPAMINE–BETA–HYDROXYLASE activity in man
  340. Central and peripheral DOPAMINE BETA HYDROXYLASE : responses to long term treatment with monoamine oxidase inhibitors
  341. Peripartum management of a patient with DOPAMINE BETA–HYDROXYLASE deficiency, a rare congenital cause of dysautonomia
  342. 1-(Substituted-benzyl) imidazole-2 (3H) thione inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  343. Association between DOPAMINE BETA‐HYDROXYLASE polymorphism and attention function in suicide attempters with chronic schizophrenia
  344. Circulating DOPAMINE–BETA–HYDROXYLASE in the rat: importance of altered disposal pathways in experimental diabetes.
  345. In vitro effect of dithiocarbamate pesticides and of CaNa2EDTA on human serum DOPAMINE–BETA–HYDROXYLASE .
  346. Effect of chronically administered nicotine on axonal transport of DOPAMINE–BETA–HYDROXYLASE in peripheral adrenergic neurons and on blood pressure and heart rate …
  347. Fumarate is the cause of the apparent ping-pong kinetics of DOPAMINE BETA–HYDROXYLASE .
  348. DOPAMINE BETA HYDROXYLASE : its relevance in the etiology of attention deficit hyperactivity disorder
  349. Inhibition by cyclopropane of release od norepinephrine, but not DOPAMINE–BETA–HYDROXYLASE , from the guinea-pig vas deferens.
  350. The effect of alpha, alpha1-dipyridyl on noradrenaline, DOPAMINE and 5-hydroxytryptamine levels and on DOPAMINE–BETA–HYDROXYLASE activity in brain.
  351. … excess and/or norepinephrine and epinephrine deficiency in autistic patients due to prenatal and/or postnatal deficiency of DOPAMINE BETA–HYDROXYLASE
  352. Serum DOPAMINE–BETA–HYDROXYLASE in manic-depressive psychosis
  353. Sleeping with and without norepinephrine: effects of metoclopramide and D, L-threo-3, 4-dihydroxyphenylserine on sleep in DOPAMINE BETA–HYDROXYLASE deficiency
  354. RNAi-mediated knock-down of the DOPAMINE BETA–HYDROXYLASE gene changes growth of razor clams
  355. Lack of correlation between serum DOPAMINE–BETA–HYDROXYLASE activity and blood pressure in middle-aged men.
  356. Immunofluorescent and biochemical studies on DOPAMINE–BETA–HYDROXYLASE and catecholamines in SIF cells of the superior cervical ganglion.
  357. Changes in human plasma catecholamines and DOPAMINE–BETA–HYDROXYLASE produced by prostaglandin F2α
  358. Immunological localization of DOPAMINE–BETA–HYDROXYLASE on the chromaffin granule membrane
  359. Neuroleptic drug effect on plasma DOPAMINE–BETA–HYDROXYLASE in schizophrenia
  360. A linkage study of affective disorder with DNA markers for the ABO-AK1-ORM linkage group near the DOPAMINE BETA HYDROXYLASE gene
  361. DOPAMINE–BETA–HYDROXYLASE activity in the axillary bodies, the heart and the splanchnic nerve in two elasmobranchs, Squalus acanthias and Etmopterus spinax.
  362. Studies on the interaction of DOPAMINE BETA–HYDROXYLASE from various sources with phytohaemagglutinins.
  363. Changes in adrenal DOPAMINE concentration after metyrapone or acth administration: Implications for the in vivo regulation of DOPAMINE BETA–HYDROXYLASE by …
  364. L–arginine alleviates postmenopausal complications in female rats by stimulating ovarian DOPAMINE BETA HYDROXYLASE
  365. Adrenergic storage vesicles in rat heart: quantitation of membrane-bound and membrane-enclosed DOPAMINE BETA–HYDROXYLASE .
  366. Changes in the expression of tyrosine HYDROXYLASE (TH), DOPAMINE BETA–HYDROXYLASE (DBH), galanin (GAL), vasoactive intestinal polypeptide (VIP) and substance P …
  367. Epinephrine and DOPAMINE BETA–HYDROXYLASE secretion from bovine adrenal.
  368. Serum DOPAMINE BETA–HYDROXYLASE activity in acute cardiac disease
  369. 1-(Thienylalkyl) imidazole-2 (3H)-thiones as potent competitive inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  370. Endoglycosidase H susceptibility of secreted and intracellular forms of DOPAMINE BETA–HYDROXYLASE .
  371. Evolution of plasma DOPAMINE–BETA–HYDROXYLASE in hypo-and hyperthyroid young rats
  372. Segregation analysis of DOPAMINE‐BETA‐HYDROXYLASE (DBH) and catechol‐o‐methyltransferase (COMT): Identification of major locus and polygenic components
  373. Modification of cerebrovascular CO2 reactivity by inhibition of DOPAMINE BETA–HYDROXYLASE .
  374. Immunofluorescence of DOPAMINE–BETA–HYDROXYLASE in small intensely fluorescent cells of human sympathetic ganglia
  375. Retrograde axonal transport of DOPAMINE BETA HYDROXYLASE antibodies by neurons in the trigeminal ganglion
  376. Substituted picolinic acids as DBH inhibitors. Inhibition of DOPAMINE BETA–HYDROXYLASE and antihypertensive action
  377. Genetic loss of norepinephrine does not alter adult hippocampal neurogenesis in DOPAMINE BETA–HYDROXYLASE deficient mice
  378. RFLP for human DBH (DOPAMINE BETA–HYDROXYLASE )
  379. … of bovine chromaffin granules in isotonic solutions of salts of weak organic acids. Release of catecholamines, ATP, DOPAMINE BETA–HYDROXYLASE , and enkephalin-like …
  380. Nerve fibers showing immunoreactivities for thyrosine HYDROXYLASE and DOPAMINE‐BETA‐HYDROXYLASE re‐appear in the guinea pig uvea after sympathectomy
  381. Plasma DOPAMINE BETA HYDROXYLASE (DBH) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading
  382. Changes in serum DOPAMINE–BETA–HYDROXYLASE activity during cold pressor test in subjects with high and low basal activity of this enzyme
  383. Lack of association between DOPAMINE BETA–HYDROXYLASE (dbh) 19-bp insertion/deletion polymorphism and risk of schizophrenia
  384. Cholinergic and GABAergic regulation of DOPAMINE BETA–HYDROXYLASE activity in the adrenal gland of the rat.
  385. Plasma and tumor DOPAMINE–BETA–HYDROXYLASE activity in patients with familial pheochromocytomas
  386. Plasma DOPAMINE–BETA–HYDROXYLASE activity and thyroid suppressibility in Graves’ disease
  387. A family study of plasma DOPAMINE–BETA–HYDROXYLASE in schizophrenia
  388. Inhibition of DOPAMINE BETA–HYDROXYLASE by 4-hydroxypyrazole: ethanol-pyrazole effects on serum DOPAMINE BETA–HYDROXYLASE in vivo.
  389. Circadian changes in adrenal DOPAMINE–BETA–HYDROXYLASE activity: dependency of change at darkness onset, and the effect of pinealectomy, on animal strain and age.
  390. An Electron Microscopic Immunocytochemical Study on the Tyrosine HYDROXYLASE ‐Positive, DOPAMINE BETA‐HYDROXYLASE ‐Negative Cells in the Pineal Gland of …
  391. Molecular forms of DOPAMINE BETA–HYDROXYLASE in rat superior cervical ganglion and adrenal gland
  392. Changes in plasma DOPAMINE BETA‐HYDROXYLASE activity induced by stimulation of the complete sympathetic outflow in the pithed rat.
  393. The influence of DOPAMINE–BETA–HYDROXYLASE inhibitors on avoidance reaction in rat.
  394. Effects of prolonged disulfiram treatment on plasma DOPAMINE–BETA–HYDROXYLASE activity in rhesus monkeys.
  395. Noradrenaline and DOPAMINE–BETA–HYDROXYLASE levels in rat salivary glands after preganglionic nerve stimulation: Evidence for re-use of amine storage granules in …
  396. Alterations in plasma DOPAMINE–BETA–HYDROXYLASE and catecholamine concentrations during surgical removal of pheochromocytoma.
  397. Development of DOPAMINE‐BETA‐HYDROXYLASE —positive fiber innervation in co‐cultured hippocampus‐locus coeruleus organotypic slices
  398. Lithium: effects of short-term and chronic treatments in rats on the activity of DOPAMINE–BETA–HYDROXYLASE (DBH) in the central versus peripheral nervous system
  399. Synthesis of several 2-substituted 3-(p-hydroxyphenyl)-1-propenes and their characterization as mechanism-based inhibitors of DOPAMINE BETA–HYDROXYLASE .
  400. Mechanism-based inhibition of DOPAMINE-. BETA.-HYDROXYLASE
  401. From gene to disease; DOPAMINE–BETA–HYDROXYLASE deficiency and orthostatic hypotension
  402. Congenital DOPAMINE BETA–HYDROXYLASE deficiency
  403. Cerebrospinal fluid norepinephrine and DOPAMINE–BETA–HYDROXYLASE in affective illness and schizophrenia
  404. Serum DOPAMINE–BETA–HYDROXYLASE activity in a new strain of spontaneously hypertensive rats
  405. Mechanistic and Structural Studies of DOPAMINE BETA–HYDROXYLASE
  406. Effects of short-term lithium treatment in rats on the activity of DOPAMINE–BETA–HYDROXYLASE in various brain regions.
  407. DOPAMINE–BETA–HYDROXYLASE activity in serum of patients with hepatic damage.
  408. Construction of Nursing Intervention Model and Clinical Empirical Study on DOPAMINE BETA HYDROXYLASE Gene Polymorphism in Children with ADHD
  409. Benzofurans as mechanism-based inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  410. Effects of phenyl-2-aminoethyl sulfide, a novel DOPAMINE–BETA–HYDROXYLASE substrate, on the cardiovascular system of the anesthetized dog.
  411. Effect of BETA-adrenergic blockade on plasma DOPAMINE–BETA–HYDROXYLASE activity and triiodothyronine in hyperthyroidism
  412. Measurements of noradrenaline overflow and DOPAMINE–BETA–HYDROXYLASE activity in superfused preparations [proceedings]
  413. Catecholamine‐containing, DOPAMINE‐BETA‐HYDROXYLASE ‐immunoreactive perivascular nerve specializations in the rat kidney
  414. Changes in serum DOPAMINE BETA HYDROXYLASE activity related to coma.
  415. Pharmacological action of FD-008, a new DOPAMINE–BETA–HYDROXYLASE inhibitor. III. Effects on endogenous biogenic amine levels in rats.
  416. DOPAMINE–BETA–HYDROXYLASE (DBH) AND PUPILLARY SYMPATHETIC ACTIVITY IN IDIOPATHIC TORSION DYSTONIA (ITD)
  417. Plasma noradrenalin and DOPAMINE–BETA–HYDROXYLASE during behavioral testing of sexually deviant XYY and XXY males
  418. Relationship between DOPAMINE–BETA–HYDROXYLASE gene polymorphism and hypertensive disorder complicating pregnancy
  419. Synthesis of 6-alkylaminopyridazine-3-carboxylic acid derivatives as DOPAMINE BETA–HYDROXYLASE inhibitors
  420. Metabolic clearance rate of DOPAMINE BETA–HYDROXYLASE in the rat.
  421. DOPAMINE–BETA–HYDROXYLASE activity in adrenal gland and spleen of rats after fasting and cold exposure
  422. Modification of plasma DOPAMINE–BETA–HYDROXYLASE activity by adrenal and pineal extirpations, and time of day dependency of changes.
  423. DOPAMINE BETA‐HYDROXYLASE activity in cerebrospinal fluid of idiopathic torsion dystonia
  424. Effect of butobendin on DOPAMINE BETA–HYDROXYLASE in vitro.
  425. DOPAMINE BETA HYDROXYLASE . Value and limits of its study in neurology
  426. Effect of DOPAMINE–BETA–HYDROXYLASE inhibitor (disulfiram) on the response of adenohypophysis, serum ceruloplasmin and hypothalamic ascorbic acid to estradiol …
  427. DOPAMINE–BETA–HYDROXYLASE effectors in neuroblastoma
  428. Comparison of physico-chemical properties of two forms of DOPAMINE–BETA–HYDROXYLASE from chromaffin granules
  429. Proceedings: The mechanism of the effect of DOPAMINE–BETA–HYDROXYLASE inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia.
  430. Responses of plasma renin activity and DOPAMINE–BETA–HYDROXYLASE to increased intravascular volume
  431. Low serum DOPAMINE—BETA–HYDROXYLASE activity in patients with panic disorder
  432. Antiarrhythmic efficiency of Craviten and changes in the activities of serum DOPAMINE BETA–HYDROXYLASE and erythrocyte membrane ATPases.
  433. DOPAMINE–BETA–HYDROXYLASE activity after acute myocardial infarction.
  434. Control of Synthesis, Transport and Release of DOPAMINE–BETA–HYDROXYLASE and Tyrosine HYDROXYLASE
  435. DOPAMINE BETA–HYDROXYLASE activity in cerebrospinal fluid of hydrocephalic patients
  436. Plasma DOPAMINE–BETA–HYDROXYLASE activity in spasmodic torticollis
  437. Serum DOPAMINE–BETA–HYDROXYLASE activity in fasting man.
  438. Anion activation of DOPAMINE BETA–HYDROXYLASE : a kinetic model.
  439. Structural and kinetic studies of bovine DOPAMINE BETA–HYDROXYLASE
  440. Plasma DOPAMINE–BETA–HYDROXYLASE in neuroblastoma.
  441. Effects of Herbal Drugs on Bovine Adrenal Tyrosine HYDROXYLASE and DOPAMINE (II)
  442. Structural study of DOPAMINE BETA HYDROXYLASE purified from human serum
  443. Biosynthesis, glycosylation and cellular sorting of human DOPAMINE BETA–HYDROXYLASE .
  444. Plasma catecholamine concentration and DOPAMINE–BETA–HYDROXYLASE activity during haemodialysis with acetate or bicarbonate at different sodium concentrations in …
  445. Developmental pattern of DOPAMINE BETA–HYDROXYLASE induction in the adrenals of the rat. Influence of neonatal hypothyroidism.
  446. Studies on the stability of an enzyme-inhibitor complex using a mechanism-based inhibitor of DOPAMINE. BETA.-HYDROXYLASE
  447. Sympathoadrenal activity and plasma glucose effects on plasma DOPAMINE–BETA–HYDROXYLASE levels in rats
  448. Lymphocyte BETA-adrenoreceptor function in congestive heart failure: modulation by DOPAMINE–BETA–HYDROXYLASE
  449. Interaction of central neurotransmitters in the regulation of adrenal DOPAMINE BETA–HYDROXYLASE
  450. Changes in plasma DOPAMINE–BETA–HYDROXYLASE activity in patients with acute subarachnoid hemorrhage (author’s transl)
  451. Preparations of human DOPAMINE BETA HYDROXYLASE subunits and antibodies against these subunits (author’s transl)
  452. Using plasma DOPAMINE BETA–HYDROXYLASE activity and its interrelations with bioelement content to predict depression in the rat model
  453. Clinical and Functional Implications of the Arg549Cys (rs6271) Polymorphism in DOPAMINE BETA–HYDROXYLASE
  454. Brain DOPAMINE BETA HYDROXYLASE Activity In Vivo: Pharmacological, Endocrinological, and Psychological Implications for Adaptation
  455. Regulation of the translation and processing of rat DOPAMINE BETA–HYDROXYLASE by metal ions in a cell free system.
  456. DOPAMINE BETA–HYDROXYLASE
  457. Plasma DOPAMINE BETA HYDROXYLASE activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha ergocriptine (Parlodel).
  458. Implication of cerebral DOPAMINE–BETA HYDROXYLASE for cardiovascular and mood regulation in rats
  459. The stimulated release of DOPAMINE–BETA–HYDROXYLASE from intact organs of normo-and hypertensive rats [proceedings].
  460. Co-expression pattern of DOPAMINE BETA–HYDROXYLASE (DβH) and neuropeptide Y (NPY) within sympathetic innervation of ovary and umbilical cord of the European …
  461. DOPAMINE–BETA–HYDROXYLASE activity in plasma, spleen and adrenal gland of streptozotocin-diabetic rats: correlation with cataracts.
  462. DYNAMICS OF PLASMA AND LYMPH DOPAMINE–BETA–HYDROXYLASE AS RELATED TO SYMPATHETIC NERVOUS SYSTEM ACTIVITY.
  463. Serum DOPAMINE BETA HYDROXYLASE (DβH) enzyme activity changes within individual women according to stage of pregnancy: Evidence that regulation of expression …
  464. The effects of some DOPAMINE–BETA–HYDROXYLASE inhibitors on the control mechanisms of the estrous cycle in rats.
  465. Alteration of blood DOPAMINE–BETA–HYDROXYLASE activity in patients with intrahepatic portal hypertension
  466. An Association Study between Four Polymorphisms in the DOPAMINE BETA–HYDROXYLASE Gene and Schizophrenia in Korean Population
  467. Catecholamines and the DOPAMINE–BETA–HYDROXYLASE activity of the blood plasma in motor pathology in children: the role of central and peripheral mechanisms
  468. Activity of plasma DOPAMINE–BETA–HYDROXYLASE and urine excretion of catecholamines in patients with deficiency-cold and deficiency-heat syndromes
  469. The 444G/A and-1021 C/T polymorphisms of the DOPAMINE–BETA–HYDROXYLASE gene modulate the trajectory of alcohol dependence development
  470. A family-based and case-control association study of the DOPAMINE BETA HYDROXYLASE gene polymorphism in attention deficit hyperactivity disorder
  471. DOPAMINE–BETA–HYDROXYLASE inhibitors, feeding and locomotir activity: Reinstatement of feeding following central norepinephrine
  472. Effect of substance P on DOPAMINE–BETA–HYDROXYLASE and phenethanolamine-N-methyltransferase in the adrenal glands of rats
  473. The Role of the DOPAMINE BETA–HYDROXYLASE Functional Polymorphism in Patients with Early-Onset Parkinson’s Disease in the Turkish Population
  474. Noradrenergic innervation of rat neocortex during development: immunocytochemical evidence using anti-DOPAMINE–BETA–HYDROXYLASE antibodies
  475. Ontogeny of epinephrine, norepinephrine, DOPAMINE–BETA–HYDROXYLASE , and chromogranin A in the adrenal gland of pigs.
  476. Proceedings: Effect of DOPAMINE–BETA–HYDROXYLASE inhibitors and centrally administered noradrenaline on (+)-amphetamine anorexia in mice.
  477. The activity of monoamine oxidase in the interscapular brown adipose tissue and DOPAMINE–BETA–HYDROXYLASE in the serum depends on the rat thyroid status
  478. Deglycosylation of DOPAMINE. BETA.-HYDROXYLASE
  479. Subclassification of hyperactive children on the basis of minor physical anomalies and plasma DOPAMINE–BETA–HYDROXYLASE activity: An attempted replication
  480. Asymmetrical content of DOPAMINE–BETA–HYDROXYLASE and phenylethanolamine-N-methyltransferase in the adrenals of spontaneously hypertensive and normotensive …
  481. Effects of DOPAMINE BETA HYDROXYLASE Levels in a Mouse Model of FD
  482. STRUCTURAL STUDIES OF DOPAMINE BETA–HYDROXYLASE
  483. Hydrazines as inhibitors of DOPAMINE. BETA.-HYDROXYLASE
  484. Role of DOPAMINE–BETA–HYDROXYLASE in DOPAMINE metabolism in the heart
  485. MECHANISM-BASED INHIBITION OF DOPAMINE BETA–HYDROXYLASE
  486. Kinetic properties of membrane DOPAMINE–BETA–HYDROXYLASE .
  487. … ) antidepressants? Despite the ability of the major metabolite of disulfiram (diethyldithiocarbamate) to inhibit the enzyme DOPAMINE BETA–HYDROXYLASE and a report of …
  488. DOPAMINE BETA–HYDROXYLASE activity after subarachnoid hemorrhage
  489. DOPAMINE–BETA–HYDROXYLASE in patients with cystic fibrosis
  490. Plasma DOPAMINE–BETA–HYDROXYLASE activity during labour in women.
  491. KINETIC STUDIES ON THE MECHANISMS OF TYROSINE HYDROXYLASE AND DOPAMINE BETA–HYDROXYLASE
  492. DOPAMINE BETA–HYDROXYLASE Deficiency GeneReview–Diagnosis: Additional Tests/Findings
  493. Ophthalmic Findings in Patients with DOPAMINE BETA–HYDROXYLASE Deficiency
  494. STRUCTURAL ANALYSIS OF THE SOLUBLE FORM OF BOVINE DOPAMINE BETA–HYDROXYLASE
  495. DOPAMINE–BETA–HYDROXYLASE : NOVEL SUBSTRATES, INHIBITORS AND MECHANISTIC STUDIES.
  496. Plasma DOPAMINE BETA–HYDROXYLASE activity in clinically healthy children
  497. Screening of DOPAMINE inhibitory activity from various wild plants
  498. Biolchemical mechanism of the toxicity of dithiocarbamate series fungicides: The inhibitory action on DOPAMINE BETA–HYDROXYLASE activity.
  499. … MONOSODIUM GLUTAMATE ON BRAIN TYROSINE HYDROXYLASE , DOPAMINE—HYDROXYLASE , TRYPTOPHAN HYDROXYLASE AND MONOAMINE OXIDSE …
  500. The regulation of alpha-synuclein on tyrosine HYDROXYLASE or DOPAMINE BETA HYDROXYLASE
  501. ISOLATION AND STRUCTURAL COMPARISONS OF SOLUBLE AND MEMBRANE-BOUND DOPAMINE–BETA–HYDROXYLASE PROTEINS FROM HUMAN AND …
  502. Plasma DOPAMINE–BETA–HYDROXYLASE as an index of peripheral noradrenergic activity
  503. Etamicastat, a new DOPAMINE BETA–HYDROXYLASE inhibitor: Pharmacological characterization
  504. Determination of DOPAMINE–BETA–HYDROXYLASE activity in human placenta at early stage
  505. PLASMA DOPAMINE–BETA–HYDROXYLASE ACTIVITY IN TOURETTE’S DISORDER AND CHRONIC MOTOR TIC DISORDER
  506. DOPAMINE BETA–HYDROXYLASE and BETA 2-microglobulin in cerebrospinal fluid: early markers in Parkinson’s disease?
  507. A Study on Serum DOPAMINE—HYDROXYLASE Activity and Thermostability in a Randomly Selected Population of Adults
  508. Correlation between the DOPAMINE–BETA–HYDROXYLASE activity and the level of plasma catecholamines during muscular exercise
  509. Effect of zamicastat, a DOPAMINE BETA–HYDROXYLASE inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
  510. Plasma DOPAMINE–BETA–HYDROXYLASE (DBH) activity in two kinds of acute stress in rabbits.
  511. Determination of the adrenergic response by measurement of catecholamines and activity of DOPAMINE–BETA–HYDROXYLASE (D-BETA-B) in arterial capillary blood
  512. STRUCTURAL AND ENZYMATIC STUDIES OF DOPAMINE–BETA–HYDROXYLASE FROM BOVINE ADRENAL CHROMAFFIN GRANULES.
  513. Activity of plasma DOPAMINE–BETA–HYDROXYLASE in newborn infants. Implication in prematurity, maternal pathology and growth
  514. THE CORRELATION BETWEEN ONTOGENESIS OF PLASMA $ DOPAMINE-{BETA}-HYDROXYLASE $ ACTIVITY AND PSYCHOPATHOLOGY IN INFANTILE AUTISM
  515. Investigation of acquired hearing loss in DOPAMINE BETA HYDROXYLASE (DBH)-mutant mice
  516. Varied mechanisms of estradiol mediated regulation of DOPAMINE BETA‐HYDROXYLASE (DBH) gene transcription
  517. DOPAMINE BETA–HYDROXYLASE activity and its interrelations with bioelements in serum of rats after electroconvulsive shock therapy
  518. Acupuncture Improves Withdrawal Symptoms by Inhibiting Tyrosine HYDROXYLASE and DOPAMINE–BETA–HYDROXYLASE Expression in the Midbrain of Heroin Re-addicted …
  519. CEREBROSPINAL FLUID NOREPINEPHRINE AND DOPAMINE–BETA–HYDROXYLASE IN AFFECTIVE ILLNESS AND SCHIZOPHRENIA
  520. Polymorphisms of the DOPAMINE BETA–HYDROXYLASE (DBH) gene show associations with cognitive flexibility in mentally healthy adults
  521. Differences in the retrograde axonal transport of nerve growth factor and DOPAMINE BETA‐HYDROXYLASE
  522. Targeting of sympathetic neurons in vivo with an anti-DOPAMINE BETA–HYDROXYLASE immunotoxin.
  523. Relationship Between Electroencephalographic (EEG) Synchronization and Plasma DOPAMINE–BETA–HYDROXYLASE (DBH) Activity in Patients
  524. The effect of one-time and repeated starvation on DOPAMINE BETA–HYDROXYLASE serum activity in rats of various ages
  525. Pharmacological inhibition of DOPAMINE BETA‐HYDROXYLASE blocks cocaine‐induced reinstatement in rats
  526. Electron transfer to DOPAMINE BETA–HYDROXYLASE in chromaffin granule membranes.
  527. Changes in human plasma DOPAMINE–BETA–HYDROXYLASE activity after ketamine and halothane anesthesia.
  528. Changes of DOPAMINE–BETA–HYDROXYLASE and activator protein-2 expression in spinal cord of formalin-induced rat pain model
  529. Synthesis of potential inhibitors of DOPAMINE–BETA–HYDROXYLASE : Heterocyclic analogues and sulfur-containing derivatives of BETA-phenethylamines
  530. An Epidemiological Study of the Relationship between Serum DOPAMINE–BETA–HYDROXYLASE Activity and Urinary Noradrenaline, and Their Relationship to Blood …
  531. Platelet mono amine oxidase and plasma DOPAMINE BETA HYDROXYLASE activity in patients with Schizophrenia
  532. Synthesis of carbon‐14 and tritium labeled DOPAMINE BETA‐HYDROXYLASE inhibitors of the imidazolinethione type
  533. Changes of DOPAMINE–BETA–HYDROXYLASE and activator protein-2? expression in spinal cord of formalin-induced rat pain model
  534. Screening of Vegetables for Inhibition Activity on DOPAMINE –HYDROXYLASE (DBH) and Monoamine oxidase (MAO)
  535. Proceedings: Reduction of locomotor activity in mice by DOPAMINE–BETA–HYDROXYLASE inhibitors–evidence against the involvement of non-specific irritation.
  536. Regulatory mechanisms of DOPAMINE BETA–HYDROXYLASE gene expression: Noradrenergic neuron-specific gene regulation
  537. Tyrosine HYDROXYLASE , DOPAMINE–BETA–HYDROXYLASE and Phenylethanolamine-N-Methyltransferase Immunoreactive Neurons of the Medulla Oblongata in the …
  538. Effects of DOPAMINE BETA‐HYDROXYLASE (DBH) inhibition on cocaine‐induced reinstatement in squirrel monkeys
  539. Synthesis of 5-(substituted alkyl) picolinic acids, the DOPAMINE. BETA.-HYDROXYLASE inhibitors. I.
  540. Distribution of DOPAMINE–BETA HYDROXYLASE (DBH) immunoreactivity in male zebra finch brains: Effects of hormone and DSP-4 treatments
  541. Muscarinic regulation of the stimulated release of norepinephrine and DOPAMINE–BETA–HYDROXYLASE from sympathetic nerves to the heart.
  542. COMPARISONS OF PURIFIED DOPAMINE–BETA–HYDROXYLASE FROM BOVINE LARGE DENSE CORED NORADRENERGIC VESICLES AND …
  543. Genetics of autism: the maternal genotype at the DOPAMINE BETA HYDROXYLASE locus may be a factor in the etiology of autism and related pervasive developmental …
  544. Total Kininogen Levels, Plasma Renin Activity, DOPAMINE–BETA–HYDROXYLASE and Plasma Catecholamines in Chronic and Acute Renal Failure
  545. Alterations in DOPAMINE BETA–HYDROXYLASE (DBH) activity, TAS (Total Antioxidative Status), Mg and Zn contents in human serum after Zn supplementation
  546. DOPAMINE BETA–HYDROXYLASE : STRUCTURAL AND KINETIC STUDIES ON THE SOLUBLE AND MEMBRANOUS FORMS OF ENZYME FROM BOVINE …
  547. … T, Blazekovic A, Perkovic MN, Jercic KG, Sustar A, Smircic-Duvnjak L, Outeiro TF, Pivac N, Borovecki F. The influence of DOPAMINE–BETA–HYDROXYLASE and catechol O …
  548. … biological activity using an allogeneic intervertebral disc supplemented with transfected nucleus pulposus cells expressing exogenous DOPAMINE BETA–HYDROXYLASE .
  549. Selective Ablation of DOPAMINE BETA–HYDROXYLASE Neurons (Subpopulation of TH Neurons) in the Brain: New Insights into Brain Catecholaminergic Circuitry and …
  550. Comparative studies of urinary electrolyte excretion, the renin-angiotensin-aldosterone system and plasma DOPAMINE–BETA–HYDROXYLASE activity in patients with …
  551. … ADRENAL CHROMAFFIN GRANULE MEMBRANES FOLLOWING SECRETION (VESICLE, EXOCYTOSIS, CATECHOLAMINE, DOPAMINE–BETA–HYDROXYLASE …
  552. Activity of the adrenergic nervous system in the pathophysiology of pregnancy and labor. I. DOPAMINE BETA–HYDROXYLASE (DBH) activity in the plasma of women with …
  553. … monocytogenes and Mycobacterium tuberculosis-dendritic cells as an “Achilles’ Heel” and immune deficiency in DOPAMINE BETA–HYDROXYLASE knock-out mice
  554. Syntheses and enzymatic studies of novel substrate analogs of phenylalanine HYDROXYLASE and DOPAMINE BETA monooxygenase

Related Posts

Shopping Cart
Scroll to Top